Identification of potential cervical cancer serum biomarkers in Thai patients

Keeratichamroen, Siriporn; Subhasitanont, Pantipa; Chokchaichamnankit, Daranee; Weeraphan, Churat; Saharat, Kittirat; Sritana, Narongrit; Kantathavorn, Nuttavut; Wiriyaukaradecha, Kriangpol; Sricharunrat, Thaniya; Paricharttanakul, N. Monique; Auewarakul, Chirayu; Svasti, Jisnuson; Srisomsap, Chantragan

doi:10.3892/ol.2020.11519

Cited by 17 publications

(23 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multimerin1 ( MMRN1 ) is a di‐sulphide linked homo‐polymeric glycoprotein from EMILIN family. Altered expression of MMRN1 has been reported in hepatocellular carcinoma, cervical cancer and ovarian cancer 52,53 . MMRN1 also played an important risk factor in gastric cancer microenvironment 54 .…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of tumour microenvironment‐related genes by TCGA database in rectal cancer

Liu

et al. 2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

Rectal cancer is a common malignant tumour and the progression is highly affected by the tumour microenvironment (TME). This study intended to assess the relationship between TME and prognosis, and explore prognostic genes of rectal cancer. The gene expression profile of rectal cancer was obtained from TCGA and immune/stromal scores were calculated by Estimation of Stromal and Immune cells in Malignant Tumors using Expression data (ESTIMATE) algorithm. The correlation between immune/stromal scores and survival time as well as clinical characteristics were evaluated. Differentially expressed genes (DEGs) were identified according to the stromal/immune scores, and the functional enrichment analyses were conducted to explore functions and pathways of DEGs. The survival analyses were conducted to clarify the DEGs with prognostic value, and the protein‐protein interaction (PPI) network was performed to explore the interrelation of prognostic DEGs. Finally, we validated prognostic DEGs using data from the Gene Expression Omnibus (GEO) database by PrognoScan, and we verified these genes at the protein levels using the Human Protein Atlas (HPA) databases. We downloaded gene expression profiles of 83 rectal cancer patients from The Cancer Genome Atlas (TCGA) database. The Kaplan‐Meier plot demonstrated that low‐immune score was associated with worse clinical outcome (P = .034), metastasis (M1 vs. M0, P = .031) and lymphatic invasion (+ vs. ‐, P < .001). A total of 540 genes were screened as DEGs with 539 up‐regulated genes and 1 down‐regulated gene. In addition, 60 DEGs were identified associated with overall survival. Functional enrichment analyses and PPI networks showed that the DEGs are mainly participated in immune process, and cytokine‐cytokine receptor interaction. Finally, 19 prognostic genes were verified by GSE17536 and GSE17537 from GEO, and five genes (ADAM23, ARHGAP20, ICOS, IRF4, MMRN1) were significantly different in tumour tissues compared with normal tissues at the protein level. In summary, our study demonstrated the associations between TME and prognosis as well as clinical characteristics of rectal cancer. Moreover, we explored and verified microenvironment‐related genes, which may be the potential key prognostic genes of rectal cancer. Further clinical samples and functional studies are needed to validate this finding.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of tumour microenvironment‐related genes by TCGA database in rectal cancer

Liu

et al. 2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…MMRN1s potential as a biomarker in certain cancers, including diagnosis of cancer stages, is a strong possibility (23)(24)(25)105). However, detail on MMRN1 protein interactions and involvement in signalling events is required to describe MMRN1 molecular mechanisms and if and how this correlates with its differential expression.…”

Section: Future Directions On the Functional Roles Of Mmrn1mentioning

confidence: 99%

“…These functions, however, shall not be covered in the current article as these have already been reviewed (22). Instead, the focus will be on MMRN1's non-platelet related functions, including mmrn1 differential gene expression and its proposed use as a cancer biomarker (23)(24)(25). A bibliometric network analysis illustrates how the research on MMRN1's platelet-related…”

mentioning

confidence: 99%

“…MMRN1 is also expressed by various cancer cell lines. Despite such analyses and clinical observations of MMRN1 differential expression in cancer (24,25) the molecular mechanisms driving these changes are currently unknown and raises various interact with tumour cells via protein-protein interactions? This review is intended to provide an overview of the state of the art in this field, with the aim to provide information towards addressing these questions in future.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Multimerin-1 and cancer: a review

Posner

2022

Bioscience Reports

View full text Add to dashboard Cite

Multimerin-1 (MMRN1) is a platelet protein with a role in haemostasis and coagulation. It is also present in endothelial cells and the extracellular matrix, where it may be involved in cell adhesion, but its molecular functions and protein-protein interactions in these cellular locations have not been studied in detail yet. In recent years, MMRN1 has been identified as a differentially expressed gene in various cancers and it has been proposed as a possible cancer biomarker. Some evidence suggests that MMRN1 expression is regulated by methylation, protein interactions, and non-coding RNAs in different cancers. This raises the questions if a functional role of MMRN1 is being targeted during cancer development, and if MMRN1’s differential expression pattern correlates with cancer progression. As a result, it is timely to review the current state of what is known about MMRN1 to help inform future research into MMRN1’s molecular mechanisms in cancer.

show abstract

“…Western blots (immunoblots) that allow separating proteins electrophoretically prior to detection are irreplaceable in cervical cancer research but have low clinical utility [57] due to difficulties with large-scale automation. Despite recent developments, where capillary electrophoresis is used to separate and chemiluminescence to detect and quantify proteins in an automated setup, it is still considered a research tool [58].…”

Section: Immunoassaysmentioning

confidence: 99%

Molecular markers for cervical cancer screening

Güzel

Hoff

Kok

et al. 2021

Expert Review of Proteomics

View full text Add to dashboard Cite

This review gives an overview of current screening practices for cervical cancer. In the introduction, we will cover approaches of population screening focusing on high-risk Human Papilloma Virus (hrHPV) and the need for a better triage assay. We will further assess the impact of current vaccination programs on screening. Subsequently, the review will cover various technological aspects of nucleic acid-and protein-based biomarker assays. We will then detail different molecular markers in view of their use in triage assays, emphasizing epigenetic and protein markers. Finally, we will place this in the context of cost-effectiveness considerations in view of their implementation in high-as well as in low-to middle-income countries. Introduction: Cervical cancer remains a significant healthcare problem, notably in low-to middle-income countries. While a negative test for hrHPV has a predictive value of more than 99.5%, its positive predictive value is less than 10% for CIN2+ stages. This makes the use of a so-called triage test indispensable for population-based screening to avoid referring women, that are ultimately at low risk of developing cervical cancer, to a gynecologist. This review will give an overview of tests that are based on epigenetic marker panels and protein markers. Areas covered: There is a medical need for molecular markers with a better predictive value to discriminate hrHPV-positive women that are at risk of developing cervical cancer from those that are not. Areas covered are epigenetic and protein markers as well as health economic considerations in view of the fact that most cases of cervical cancer arise in low-to-middle-income countries. Expert opinion: While there are biomarker assays based on changes at the nucleic acid (DNA methylation patterns, miRNAs) and at the protein level, they are not widely used in population screening. Combining nucleic acid-based and protein-based tests could improve the overall specificity for discriminating CIN2+ lesions that carry a low risk of progressing to cervical cancer within the screening interval from those that carry an elevated risk. The challenge is to reduce unnecessary referrals without an undesired increase in false-negative diagnoses resulting in cases of cervical cancer that could have been prevented. A further challenge is to develop tests for low-and middle-income countries, which is critical to reduce the worldwide burden of cervical cancer.

show abstract

Identification of potential cervical cancer serum biomarkers in Thai patients

Cited by 17 publications

References 49 publications

Prognostic value of tumour microenvironment‐related genes by TCGA database in rectal cancer

Prognostic value of tumour microenvironment‐related genes by TCGA database in rectal cancer

Multimerin-1 and cancer: a review

Molecular markers for cervical cancer screening

Contact Info

Product

Resources

About